This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CLSD Clearside Biomedical (CLSD) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsInsider TradesOwnershipTrendsBuy This Stock About Clearside Biomedical Stock (NASDAQ:CLSD) Get Clearside Biomedical alerts:Sign Up Key Stats Today's Range$0.41▼$0.4150-Day Range$0.36▼$4.0752-Week Range$0.37▼$14.09VolumeN/AAverage Volume220,545 shsMarket Capitalization$2.15 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingReduce Company Overview Clearside Biomedical, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for diseases affecting the back of the eye. The company’s proprietary SCS Microinjector® platform enables targeted delivery of therapeutics into the suprachoroidal space, a potential route to enhance local drug exposure while minimizing off-target effects. Clearside’s approach is designed to address a range of retinal disorders by directly depositing medication adjacent to choroid and retina. The company’s lead approved product is XIPERE® (triamcinolone acetonide injectable suspension), which has received U.S. Food and Drug Administration clearance for the treatment of macular edema associated with uveitis. In addition to XIPERE, Clearside has advanced several pipeline candidates, including CLS-AX (axitinib injectable suspension) for neovascular age-related macular degeneration and other small-molecule and biologic programs leveraging the suprachoroidal route. These programs are in various stages of clinical development, targeting indications such as diabetic macular edema and wet AMD. Founded in 2010 and headquartered in Alpharetta, Georgia, Clearside Biomedical completed its initial public offering on the Nasdaq Stock Market under the ticker “CLSD.” The company is led by President and Chief Executive Officer Samir Melhem, who has overseen clinical and regulatory milestones, including FDA approval of XIPERE. Clearside continues to explore both U.S. and ex-U.S. partnerships to expand patient access to its suprachoroidal therapies.AI Generated. May Contain Errors. Read More Receive CLSD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clearside Biomedical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CLSD Stock News HeadlinesClearside Biomedical, Inc. Completes Financial Restructuring and Emerges from Chapter 11 with Steel Partners as Plan SponsorJuly 14, 2026 | businesswire.comClearside Biomedical Faces Delisting After Bankruptcy FilingNovember 25, 2025 | msn.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.August 13 at 1:00 AM | Banyan Hill Publishing (Ad)Clearside Biomedical to pursue sale of business via Chapter 11 processNovember 24, 2025 | msn.comClearside Biomedical, Inc. Files Chapter 11 Bankruptcy to Pursue Asset Sale and Maximize Stakeholder ValueNovember 24, 2025 | quiverquant.comQClearside Biomedical to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 ProcessNovember 24, 2025 | globenewswire.comClearside Biomedical Regains Nasdaq Compliance as of October 2025October 7, 2025 | tipranks.comClearside Biomedical (CLSD) Price Target Increased by 1,400.00% to 64.26September 30, 2025 | msn.comSee More Headlines CLSD Stock Analysis - Frequently Asked Questions How were Clearside Biomedical's earnings last quarter? Clearside Biomedical, Inc. (NASDAQ:CLSD) posted its quarterly earnings results on Friday, November, 14th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by $0.47. The company had revenue of $0.20 million for the quarter, compared to analyst estimates of $0.09 million. When did Clearside Biomedical's stock split? Clearside Biomedical's stock reverse split before market open on Monday, September 15th 2025.The 1-15 reverse split was announced on Thursday, September 11th 2025. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 12th 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Clearside Biomedical IPO? Clearside Biomedical (CLSD) raised $50 million in an initial public offering on Thursday, June 2nd 2016. The company issued 7,200,000 shares at a price of $7.00 per share. Cowen and Company and Stifel acted as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager. What other stocks do shareholders of Clearside Biomedical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Clearside Biomedical investors own include Northwest Biotherapeutics (NWBO), Ocular Therapeutix (OCUL), NVIDIA (NVDA), T2 Biosystems (TTOO), Advanced Micro Devices (AMD) and Company Calendar Last Earnings11/14/2025Today8/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (8m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 CLSD's financial health is in the Red zone, according to TradeSmith. CLSD has been in this zone for over 8 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CLSD CIK1539029 Webwww.clearsidebio.com Phone(678) 270-3631Fax678-270-4033Employees30Year Founded2011Profitability EPS (Trailing Twelve Months)($5.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$34.35 million Net Margins-665.19% Pretax Margin-648.06% Return on EquityN/A Return on Assets-124.15% Debt Debt-to-Equity RatioN/A Current Ratio3.87 Quick Ratio3.87 Sales & Book Value Annual Sales$3.33 million Price / Sales0.64 Cash FlowN/A Price / Cash FlowN/A Book Value($7.68) per share Price / Book-0.05Miscellaneous Outstanding Shares5,234,000Free Float4,886,000Market Cap$2.15 million OptionableOptionable Beta2.04 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:CLSD) was last updated on 8/13/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clearside Biomedical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Clearside Biomedical With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CLSD Stock Alerts